Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018 2019 2020

Details for Mechanism ID: 18203
Country/Region: Kenya
Year: 2016
Main Partner: Elizabeth Glaser Pediatric AIDS Foundation
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: HHS/CDC
Total Funding: $16,960,431 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $2,144,316
Care: Orphans and Vulnerable Children (HKID) $274,461
Care: TB/HIV (HVTB) $643,649
Care: Pediatric Care and Support (PDCS) $381,725
Laboratory Infrastructure (HLAB) $70,000
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $1,764,880
Biomedical Prevention: Injection Safety (HMIN) $30,000
Testing: HIV Testing and Counseling (HVCT) $1,055,998
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $1,419,257
Treatment: Adult Treatment (HTXS) $8,603,558
Treatment: Pediatric Treatment (PDTX) $572,587
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST Age/sex: <1 2017 14,977
HTS_TST Age/sex: 1-9 2017 622,900
HTS_TST Age/sex: 10-14 Female 2017 110,019
HTS_TST Age/sex: 10-14 Male 2017 115,547
HTS_TST Age/sex: 15-19 Female 2017 146,338
HTS_TST Age/sex: 15-19 Male 2017 129,467
HTS_TST Age/sex: 20-24 Female 2017 306,538
HTS_TST Age/sex: 20-24 Male 2017 216,005
HTS_TST Age/sex: 25-49 Female 2017 526,646
HTS_TST Age/sex: 25-49 Male 2017 362,383
HTS_TST Age/sex: 50+ Female 2017 100,693
HTS_TST Age/sex: 50+ Male 2017 78,686
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 480,366
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 409,936
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 1,172,615
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 826,245
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 2,901,126
HTS_TST Service Delivery Point (Facility): Index testing 2017 42,317
HTS_TST Service Delivery Point (Facility): Inpatient 2017 169,863
HTS_TST Service Delivery Point (Facility): Malnutrition facilities 2017 50
HTS_TST Service Delivery Point (Facility): Other PITC 2017 23,190
HTS_TST Service Delivery Point (Facility): Outpatient 2017 1,717,359
HTS_TST Service Delivery Point (Facility): Pediatric 2017 30,713
HTS_TST Service Delivery Point (Facility): PMTCT 2017 169,078
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 6,683
HTS_TST Service Delivery Point (Facility): VCT 2017 701,187
HTS_TST Service Delivery Point (Facility): VMMC 2017 33,248
HTS_TST Sum of Age/Sex disaggregates 2017 2,092,322
HTS_TST Sum of Aggregated Age/Sex <15 2017 890,302
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 1,998,860
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 2,889,162
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Female 2017 1,522
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Male 2017 1,137
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Female 2017 3,871
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Male 2017 2,691
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Female 2017 9,744
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Male 2017 6,643
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Female 2017 17,249
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Male 2017 11,444
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Female 2017 3,824
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Male 2017 2,627
HTS_TST_POS Test Result by Age: Positive: <1 2017 9
HTS_TST_POS Test Result by Age: Positive: 1-9 2017 8,250
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 7,754
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 5,533
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 49,128
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 31,397
PMTCT_ART Already on ART at beginning of current pregnancy 2017 19,385
PMTCT_ART New on ART 2017 6,828
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 157,958
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 18,056
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 5,916
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 787
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 765
PMTCT_EID Sum of Infant Age disaggregates 2017 23,972
PMTCT_STAT By Age (DREAMS SNUs ONLY): <15 2017 649
PMTCT_STAT By Age (DREAMS SNUs ONLY): 15-19 2017 3,367
PMTCT_STAT By Age (DREAMS SNUs ONLY): 20-24 2017 21,647
PMTCT_STAT By Age (DREAMS SNUs ONLY): 25-49 2017 45,987
PMTCT_STAT By Age (DREAMS SNUs ONLY): 50+ 2017 171
PMTCT_STAT By: Known positives at entry 2017 12,883
PMTCT_STAT By: Number of new positives identified 2017 4,911
PMTCT_STAT Number of new ANC and L&D clients 2017 157,958
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 157,958
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: <15 2017 10
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 15-19 2017 128
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 20-24 2017 1,249
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 25-49 2017 7,006
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 50+ 2017 1,219
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 15-19 2017 18
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 20-24 2017 466
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 25-49 2017 2,470
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 50+ 2017 441
PMTCT_STAT Sum of Positives Status disaggregates 2017 17,794
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: <15 2017 634
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: <15-19 2017 3,373
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 20-24 2017 21,748
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 25-49 2017 46,003
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 50+ 2017 55
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 116
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 2,562
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 159
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 3,240
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 5,952
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 5,952
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 58,455
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 23
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 58,454
TB_SCREENDX Screen Result: Screened Positive for TB 2017 64,986
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 201,108
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 93,275
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 16,396
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 15,036
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 324,584
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 191
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 3,792
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 278
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 4,559
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 8,832
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 8,832
TX_CURR Age/Sex: <1 2017 612
TX_CURR Age/Sex: <1-9 2017 20,577
TX_CURR Age/Sex: 10-14 Female 2017 5,267
TX_CURR Age/Sex: 10-14 Male 2017 4,805
TX_CURR Age/Sex: 15-19 Female 2017 4,933
TX_CURR Age/Sex: 15-19 Male 2017 2,838
TX_CURR Age/Sex: 20-24 Female 2017 17,598
TX_CURR Age/Sex: 20-24 Male 2017 4,496
TX_CURR Age/Sex: 25-49 Female 2017 148,569
TX_CURR Age/Sex: 25-49 Male 2017 63,959
TX_CURR Age/Sex: 50+ Female 2017 29,333
TX_CURR Age/Sex: 50+ Male 2017 21,597
TX_CURR Aggregated Age/Sex: <15 Female 2017 16,344
TX_CURR Aggregated Age/Sex: <15 Male 2017 14,914
TX_CURR Aggregated Age/Sex: 15+ Female 2017 200,346
TX_CURR Aggregated Age/Sex: 15+ Male 2017 93,163
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 324,584
TX_CURR Sum of age/sex disaggregates 2017 7,771
TX_CURR Sum of Aggregated Age/Sex <15 2017 31,258
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 293,509
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 324,767
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 4,369
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 4,125
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 59,712
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 27,538
TX_NEW By Age/Sex: <1 2017 718
TX_NEW By Age/Sex: 1-9 2017 5,212
TX_NEW By Age/Sex: 10-14 Female 2017 1,372
TX_NEW By Age/Sex: 10-14 Male 2017 1,192
TX_NEW By Age/Sex: 15-19 Female 2017 1,493
TX_NEW By Age/Sex: 15-19 Male 2017 497
TX_NEW By Age/Sex: 20-24 Female 2017 6,596
TX_NEW By Age/Sex: 20-24 Male 2017 1,808
TX_NEW By Age/Sex: 25-49 Female 2017 43,683
TX_NEW By Age/Sex: 25-49 Male 2017 19,242
TX_NEW By Age/Sex: 50+ Female 2017 7,940
TX_NEW By Age/Sex: 50+ Male 2017 6,033
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 95,804
TX_NEW Sum of Age/Sex disaggregates 2017 89,856
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 95,744
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 292,394
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 292,187
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 14,820
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 13,748
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 180,477
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 83,712
TX_PVLS Numerator: Indication: Routine 2017 292,178
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 14,819
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 13,548
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 180,478
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 83,712
TX_PVLS_den Denominator: Indication: Routine 2017 289,182
TX_RET Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 703
TX_RET Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 4,860
TX_RET Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,279
TX_RET Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,121
TX_RET Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,387
TX_RET Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 465
TX_RET Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 5,986
TX_RET Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,748
TX_RET Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 39,626
TX_RET Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 17,471
TX_RET Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 7,227
TX_RET Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 5,498
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 4,144
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 3,858
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 54,185
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 25,094
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 87,245
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 95,722
TX_RET_den Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 723
TX_RET_den Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 5,191
TX_RET_den Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,370
TX_RET_den Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,190
TX_RET_den Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,488
TX_RET_den Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 507
TX_RET_den Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 6,574
TX_RET_den Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,843
TX_RET_den Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 43,714
TX_RET_den Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 19,205
TX_RET_den Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 7,913
TX_RET_den Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 6,005
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 4,360
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 4,114
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 59,689
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 27,560
VMMC_CIRC By Age: 10-14 2017 83,385
VMMC_CIRC By Age: 15-19 2017 40,770
VMMC_CIRC By Age: 20-24 2017 7,006
VMMC_CIRC By Age: 25-29 2017 4,028
VMMC_CIRC By Age: 30-49 2017 3,509
VMMC_CIRC By Age: 50+ 2017 356
VMMC_CIRC By circumcision technique: Device-based VMMC 2017 4,000
VMMC_CIRC By circumcision technique: Surgical VMMC 2017 135,167
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2017 139,568
VMMC_CIRC Sum of age disaggregates (FY15-Current) 2017 139,054
VMMC_CIRC Sum of age disaggregates (Prior to FY15) 2017 131,517
Cross Cutting Budget Categories and Known Amounts Total: $2,877,754
Gender: Gender Based Violence (GBV) $1,438,877
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Gender: Gender Equality $1,438,877
Equity in HIV prevention, care, treatment and support
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Operation Research